A Pilot Phase IIa Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2012
At a glance
- Drugs KD 027 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 08 Jan 2008 Status changed from recruiting to completed.
- 08 Jan 2008 Positive results have been reported in a company media release.
- 29 Jun 2007 New trial record.